August 4, 2000
The Irvine maker of products to treat cardiovascular disease said it earned $12 million, or 20 cents a share, in the second quarter, its first three-month period since being spun off from medical device maker Baxter International. For the second quarter last year, pro forma income totaled $13.7 million, or 24 cents a share. The income for the recent quarter excluded pretax charges of $362 million related to the write-down of goodwill and other assets, plus other costs such as spin-off expenses.
June 13, 2000 |
Irvine-based Edwards Lifesciences Corp., which makes products to treat heart disease, said it received approval from the Food and Drug Administration to sell its Thrombex PMT System, which removes blood clots from grafted blood vessels. The stock closed at $18.63, up 13 cents a share, on the New York Stock Exchange.
January 24, 2006 |
Edwards Lifesciences Corp. said it agreed to settle a patent dispute with Medtronic Inc. and Medtronic Vascular Inc. over grafts used to treat various aneurysms. Irvine-based Edwards said that in exchange for a payment of $37.5 million to Edwards and Australia-based Endogad Research Party Ltd., Medtronic had been granted nonexclusive licenses to the patents involved in the litigation and related patents.
September 4, 2008 |
Edwards Lifesciences Corp. won U.S. regulatory approval to sell a replacement heart valve derived from cow tissue and designed to be easier to implant because it mimics the shape of the original. The product, the Perimount Magna, will be available immediately, the Irvine company said. The valve is derived from cow hearts and uses technology that prevents calcium from building up and restricting blood flow. The Perimount Magna was introduced in Europe in 2005.
July 24, 2007 |
Edwards Lifesciences Corp. lowered its forecast for 2007 sales to the low end of the previous range of $1.07 billion to $1.11 billion. Earnings will be 41 cents to 43 cents a share in the third quarter and $2.08 to $2.12 for the year, the company said. Revenue for heart valve therapy sales will be $250 million to $260 million for the second half of the year, according to the company. Second-quarter profit fell 3.3% to $34.9 million, or 57 cents a share, the Irvine company said.
December 6, 2006 |
Edwards Lifesciences Corp. said that it had dropped its laser treatment for a type of abnormal heart rhythm and that it would cut 70 jobs and take a $16-million pretax charge as it reorganized operations. Irvine-based Edwards, best known as a maker of heart valves, said it discontinued its Optiwave 980 Cardiac Laser Ablation system designed to treat atrial fibrillation, a common but difficult-to-treat heart rhythm in which the upper chambers of the heart beat out of sync.
October 25, 2000 |
Edwards Lifesciences Corp. said Tuesday it has received clearance from the Food and Drug Administration to begin marketing its latest monitoring system, which provides a picture of blood circulation in a patient's heart. The Irvine maker of products to treat cardiovascular disease said in a press release that its Vigilance CCO/SvO2/CEDV Monitor gives gives clinicians a complete picture using a single system.
December 2, 2005 |
Edwards Lifesciences Corp. said it received U.S. regulatory approval to restart a clinical trial that would allow doctors to implant a heart valve without open-heart surgery. Edwards said the trial used a new, simpler approach and involved a larger heart valve. The 20-patient trial is designed to test the feasibility of delivering a heart valve without surgery.